|
dara+bor + dex
|
carf+len + dex
|
ixa + len + dex
|
elo + len + dex
|
carf+dex
|
bor + PLD
|
len + dex
|
thal+bor + dex
|
bor + dex + pan
|
pom + dex
|
bor
|
bor + dex
|
---|
dara+len + dex
|
0.56 (0.35,0.87)
|
0.51 (0.37,0.70)
|
0.49 (0.36,0.67)
|
0.44 (0.32,0.62)
|
0.43 (0.28,0.65)
|
0.35 (0.22,0.53)
|
0.34 (0.27,0.43)
|
0.33 (0.18,0.62)
|
0.30 (0.20,0.44)
|
0.29 (0.19,0.42)
|
0.25 (0.17,0.37)
|
0.22 (0.15,0.32)
|
dara+bor + dex
| |
0.91 (0.58,1.42)
|
0.88 (0.56,1.36)
|
0.80 (0.50, 1.24)
|
0.77 (0.56,1.06)
|
0.62 (0.37,1.06)
|
0.61 (0.40,0.90)
|
0.60 (0.33,1.08)
|
0.54 (0.39,0.74)
|
0.52 (0.32,0.83)
|
0.45 (0.28,0.72)
|
0.39 (0.30,0.50)
|
carf+len + dex
| | |
0.97 (0.73,1.27)
|
0.87 (0.64,1.18)
|
0.85 (0.56,1.29)
|
0.68 (0.44,1.04)
|
0.67 (0.55,0.82)
|
0.66 (0.35,1.20)
|
0.59 (0.41,0.85)
|
0.57 (0.39,0.83)
|
0.49 (0.34,0.71)
|
0.43 (0.29,0.61)
|
ixa + len + dex
| | | |
0.90 (0.67,1.22)
|
0.88 (0.58,1.30)
|
0.70 (0.47,1.07)
|
0.69 (0.57,0.84)
|
0.68 (0.37,1.24)
|
0.61 (0.43,0.87)
|
0.59 (0.41,0.85)
|
0.51 (0.36,0.72)
|
0.44 (0.31,0.63)
|
elo + len + dex
| | | | |
0.97 (0.63,1.50)
|
0.78 (0.51,1.22)
|
0.77 (0.61,0.96)
|
0.75 (0.41,1.39)
|
0.68 (0.47,0.99)
|
0.65 (0.44,0.96)
|
0.56 (0.39,0.82)
|
0.49 (0.33,0.72)
|
carf+dex
| | | | | |
0.80 (0.49,1.32)
|
0.79 (0.55,1.13)
|
0.78 (0.44,1.37)
|
0.70 (0.53,0.91)
|
0.67 (0.43,1.06)
|
0.58 (0.37,0.79)
|
0.50 (0.42,0.60)
|
bor + PLD
| | | | | | |
0.98 (0.68,1.42)
|
0.97 (0.49,1.89)
|
0.87 (0.55,1.37)
|
0.83 (0.56,1.24)
|
0.72 (0.58,0.91)
|
0.63 (0.39,0.99)
|
len + dex
| | | | | | | |
0.98 (0.55,1.74)
|
0.88 (0.66,1.20)
|
0.85 (0.62,1.16)
|
0.74 (0.55,0.99)
|
0.64 (0.47,0.86)
|
thal+bor + dex
| | | | | | | | |
0.90 (0.51,1.60)
|
0.86 (0.46,1.63)
|
0.75 (0.40,1.43)
|
0.65 (0.38,1.12)
|
bor + dex + pan
| | | | | | | | | |
0.96 (0.66,1.42)
|
0.83 (0.55,1.23)
|
0.72 (0.60,0.88)
|
pom + dex
| | | | | | | | | | |
0.87 (0.62,1.20)
|
0.75 (0.50,1.11)
|
bor
| | | | | | | | | | | |
0.87 (0.58,1.30)
|
- bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal thalidomide, vor vorinostat
- Significant results on the 95% level are marked in italic